Micro-Comparison
    Body Composition

    Semaglutide vs Tirzepatide for Muscle Preservation

    Losing fat is the goal. Losing muscle is the concern. Here is how semaglutide and tirzepatide compare for body composition and what you can do to protect lean mass.

    Published: April 3, 2026-9 min read

    Medical Disclaimer: This comparison is for informational purposes only. Consult your provider for personalized guidance.

    Muscle preservation during weight loss is not just about aesthetics. Maintaining lean mass supports metabolic rate, functional strength, bone density, and long-term weight maintenance. If you are choosing between semaglutide and tirzepatide, here is what the evidence says about muscle.

    Body Composition Data

    MetricSemaglutideTirzepatide
    Total weight loss~15%~21%
    Lean mass as % of loss~25-39%~25-33%
    Fat mass loss~61-75%~67-75%
    Study measurementDEXA (STEP 1)DEXA (SURMOUNT-1)

    What Matters More Than Medication Choice

    Muscle Preservation Protocol

    • High protein intake: 1.2-1.6g per kg ideal body weight daily (80-130g for most). This is the single most important factor
    • Resistance training: 2-3 sessions per week targeting major muscle groups. Progressive overload when possible
    • Adequate calories: Do not go below 1,200 cal (women) or 1,500 cal (men). Extreme restriction accelerates muscle loss
    • Creatine: 3-5g daily supports muscle retention during caloric deficit
    • Sleep: 7-9 hours per night. Growth hormone, essential for muscle maintenance, is released during sleep
    • Gradual weight loss: 1-2 lbs per week is ideal. Faster weight loss increases the lean mass percentage lost

    The Bottom Line

    Our Assessment

    The proportion of lean mass lost is similar between semaglutide and tirzepatide. Because tirzepatide produces more total weight loss, the absolute amount of lean mass lost may be higher. However, protein intake and resistance training have a far greater impact on muscle preservation than medication choice. Whichever medication you choose, prioritize protein and strength training.

    Frequently Asked Questions

    How much muscle do you lose on GLP-1?

    In clinical trials, approximately 25-40% of weight lost on GLP-1 medications is lean mass (muscle plus water). This ratio is similar to other forms of weight loss. With adequate protein (1.2-1.6g per kg body weight) and resistance training, lean mass loss can be reduced to 15-25% of total weight lost.

    Which is better for muscle preservation?

    Neither medication has a clear advantage in head-to-head data for muscle preservation. Because tirzepatide causes more total weight loss, it may result in more absolute lean mass loss, but the proportion appears similar. Protein intake and exercise are far more important than medication choice.

    How much protein should I eat on GLP-1 to preserve muscle?

    Aim for 1.2-1.6g of protein per kg of ideal body weight daily, or roughly 80-130g for most adults. This is significantly higher than typical intake and requires intentional planning since your appetite is reduced.

    What exercise preserves muscle on GLP-1?

    Resistance training (weight lifting) 2-3 times per week is the most effective strategy. Focus on compound movements: squats, deadlifts, bench press, rows, and overhead press. Even bodyweight exercises or resistance bands help. Cardio alone does not preserve muscle mass during weight loss.

    Lose Fat, Keep Muscle

    Trimi clinicians provide nutrition and exercise guidance alongside affordable GLP-1 treatment.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded tirzepatide?

    Peer-reviewed evidence: Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022). Trimi offers compounded tirzepatide starting at $125/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. — SURMOUNT-1, NEJM 2022
    In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. — SURPASS-2, NEJM 2021
    Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. — SURMOUNT-OSA, NEJM 2024

    Key Takeaways

    • Tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% at 72 weeks in adults with obesity without diabetes; the 5 mg and 10 mg doses produced 16.0% and 21.4% reductions respectively. (Source: SURMOUNT-1, NEJM 2022)
    • In a 40-week head-to-head trial of patients with type 2 diabetes, tirzepatide 15 mg produced approximately 11.2 kg of body-weight reduction vs 5.7 kg on semaglutide 1 mg. (Source: SURPASS-2, NEJM 2021)
    • Tirzepatide reduced the apnea-hypopnea index by approximately 27 to 30 events/hour at 52 weeks in adults with obesity and moderate-to-severe obstructive sleep apnea, vs roughly 5 events/hour reduction on placebo. (Source: SURMOUNT-OSA, NEJM 2024)
    • Tirzepatide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Zepbound and Mounjaro). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Semaglutide vs. Tirzepatide — 2026 Active-Ingredient Comparison

    Both are once-weekly injectable GLP-1-based weight-loss medications. Tirzepatide is a dual GIP/GLP-1 agonist with higher average weight-loss outcomes; semaglutide is a single GLP-1 agonist with stronger cardiovascular-outcomes evidence.

    Semaglutide vs. Tirzepatide — 2026 Active-Ingredient Comparison
    SemaglutideTirzepatide
    Receptor targetsGLP-1GIP + GLP-1 (dual agonist)
    Weight-loss brandWegovy (Novo Nordisk)Zepbound (Eli Lilly)
    Diabetes brandOzempic (injectable), Rybelsus (oral)Mounjaro (injectable)
    Pivotal weight-loss trialSTEP 1: 14.9% at 68 weeks (NEJM 2021)SURMOUNT-1: 20.9% at 72 weeks (NEJM 2022)
    CV-outcomes evidenceSELECT: 20% MACE reduction (NEJM 2023)SURMOUNT-CV trial ongoing
    OSA indicationNoZepbound approved Dec 2024
    Trimi compounded price$99/month (annual plan)$125/month (annual plan)

    Source: STEP 1, SURMOUNT-1, SELECT, SURPASS-2, SURMOUNT-OSA (NEJM 2021-2024)

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: February 20, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2107519
    3. Wadden TA, Chao AM, Machineni S, et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-023-02597-w
    4. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2023.24945
    5. Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2404881
    6. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information. FDA.Read Study

    Was this article helpful?

    Keep Reading

    Comprehensive comparison of retatrutide (triple agonist) vs tirzepatide (dual agonist). Compare weight loss results, mechanisms, timelines, and whether waiting for the next-generation drug makes sense

    Complete side-by-side comparison of semaglutide, tirzepatide, and retatrutide. Compare weight loss results, mechanisms, side effects, costs, and availability to find the right GLP-1 medication for you

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    Compare semaglutide and tirzepatide for polycystic ovary syndrome. Effects on insulin resistance, fertility, androgen levels, and weight loss in PCOS patients.

    Start your GLP-1 journey — from $99/mo

    Get Started